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Abstract
Purpose: To evaluate accuracy and interobserver variability in the assessment of 2-deoxy-2[F-
18]fluoro-D-glucose-positron emission tomography (FDG-PET) for detection of recurrent
laryngeal carcinoma after radiotherapy.
Procedures: Eleven experienced nuclear physicians from eight centres assessed 30 FDG-PET
scans on the appearance of local recurrence (negative/equivocal/positive). Conservative
(equivocal analysed as negative) and sensitive (equivocal analysed as positive) assessment
strategies were compared to the reference standard (recurrence within 6months after PET).
Results: Seven patients had proven recurrences. For the conservative and sensitive strategy,
the mean sensitivity was 87% and 97%, specificity 81% and 63%, positive predictive values
61% and 46% and negative predictive values 96% and 99%, respectively. Interobserver
variability showed a reasonable relation in comparison to the reference standard (kappa = 0.55).
Conclusions: FDG-PET has acceptable interobserver agreement and yields good negative
predictive value for detection of recurrent laryngeal carcinoma. It could therefore be used as first
diagnostic step and may reduce futile invasive diagnostics.
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Introduction
Laryngeal cancer is the most common primary cancer siteof the head and neck, with annually about 700 new
cases in The Netherlands [1]. Because of the relatively low
incidence and the specialised care, the vast majority of
laryngeal cancers in The Netherlands are treated in the eight
recognised head and neck cancer centres of the Dutch Head
and Neck Oncology Cooperative Group.
Parallel to developments elsewhere, non-surgical treatment
modalities in our country are more common than in the past
due to improved results of altered fractionation schedules in
radiation therapy and the addition of chemotherapy to
radiation [2–4]. The aims of non-surgical treatments are organ
preservation and improvement of quality of life [5, 6].
Especially, in this group of patients, early detection of
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residual or recurrent tumour is of critical importance because
prompt salvage surgery improves control of disease.
The diagnostic accuracy of the currently available
diagnostic techniques to diagnose persistent or recurrent
disease after (chemo)-radiotherapy is currently limited. Post-
irradiation inflammation, oedema and necrosis can hamper
the detection of residual or recurrent local tumour. CT and
MRI rely on structural changes and show a limited accuracy,
with reported sensitivities ranging from 50% to 58% and
specificities from 33% to 100% for detection of recurrent
laryngeal carcinoma [7–14]. Direct laryngoscopy under
general anaesthesia with biopsies runs the risk of complica-
tions (e.g., inducing necrosis, infection and further oedema)
when biopsies are taken from irradiated tissue and was false
negative in 31% of the initial laryngoscopies in previous
research [15].
2-Deoxy-2[F-18]fluoro-D-glucose-positron emission to-
mography (FDG-PET) is a promising technique for tumour
detection after (chemo)radiotherapy. FDG-PET seems more
accurate for the detection of recurrent head and neck
carcinomas than other diagnostic methods [10, 16–22]. The
reported sensitivity of FDG-PET for the detection of
recurrent carcinoma after (chemo)radiotherapy varies be-
tween 80% and 100% and the specificity varies between
63% and 93% [12–14, 23–28].
Evaluation of PET in these studies is typically by visual
interpretation, which is prone to observer variation. To the
best of our knowledge, no studies have been conducted to
investigate observer variation in a multi-centre setting for
this indication.
To evaluate the value of FDG-PET in the detection of
recurrent laryngeal carcinoma after radiotherapy, a rando-
mised controlled multi-centre trial was started recently
within the framework of the Dutch Head and Neck
Oncology Cooperative Group [29]. The extent to which the
future results can be generalised, and thereby foresee the
applicability of PET in daily clinical practice, tends to
depend on the degree of agreement among the observers.
Therefore, we evaluated the interobserver variability in
reporting among 11observers involved in this trial, with a
set of FDG-PET scans of patients suspected of having
recurrent laryngeal carcinoma after radiotherapy.
Materials and Methods
From the VU University Medical Center (VUmc) PET database,
we identified 30 FDG-PET scans of consecutive patients with a
clinical suspicion of persistent or recurrent laryngeal carcinoma
after radiotherapy from the year 1998 to 2000. This suspicion was
based on clinical symptoms, office laryngoscopy or diagnostic
imaging, other than FDG-PET. Patients’ T stages prior to
radiotherapy were T1 (n = 4), T2 (n = 16), T3 (n = 5) and T4
(n = 5), N stages were N0 (n = 27) and N1 (n = 3) and none of the
patients had distant metastases. The mean age at time of the PET
scan was 60.9 ± 11.1years. The median interval between the last
radiation fraction and the PET scan was 8.7months (range 2.4–
32.1months). As reference standard, we used the results of
biopsies and histology or the absence of signs of tumour within
6months after the PET scan.
PET Imaging
All patients underwent FDG-PET after at least 6-h fasting. Blood
glucose levels were measured before scanning. All patients were
non-diabetic. The median blood glucose level measured with a
glucotouch stick was 5.9 ± 1.6 mmol/l. Sixty minutes after
intravenous injection of 370MBq of 18F-FDG, imaging was
performed in a full-ring bismuth germanate oxide PET scanner
(ECAT EXACT HR+; CRI/Siemens, Erlangen, Germany). Five
patients received a dose of 555MBq because of higher weight. A
scanning track from the base of skull to the clavicles was used, i.e.
two bed positions per patient, with an acquisition time of 5min per
bed position. PET imaging was done with 2D acquisition using
Ordered Subset Expectation Maximization (OSEM 2-16) to
reconstruct the images. Attenuation correction was not applied in
our clinical practice because of the results of the systemic review
by Joshi et al. [30]. The acquired images were viewed on a local PC
of the participating centre with the PETViewer 2.0.10.570 (Micro-
soft Windows XP Professional Service Pack 2 (build 2600)).
Data Analysis
The panel of observers consisted of 11 experienced nuclear
medicine physicians from the eight Dutch Head and Neck
Oncology Cooperative Group medical centres. We recorded the
experience of the observers with FDG-PET for this indication in
terms of the estimated number of FDG-PET scans for laryngeal
cancer they had assessed. Images were reviewed at each site on
available PC running under Microsoft Windows (XP/2000). The
scans were presented with a PET-viewer that allowed variable
gamma and window tuning.
The observers were requested to interpret the PET scans as
being indicative for the presence of local residue or recurrence and
to classify the result as negative, equivocal or positive. Only
increased uptake at the site of the initial primary tumour was used
for further analyses. The observers were not provided with specific
criteria for determining positivity and negativity. Evaluation was
made on an overall basis rather than on a per-lesion basis.
The observers read the scans independently, and clinical
information (regarding TNM stage and site of the primary tumour,
last radiotherapy fraction, symptoms and the result of other
diagnostic tests) was provided to imitate the clinical setting.
Correlative anatomic imaging (CT or MRI) was not provided nor
were the reports of these scans. There was no time restriction for
the assessment. Observers were blinded for the final clinical
classification until they had reported all scans; thereafter, the
investigator (LvdP) provided them with these results to improve
standardised reading during the following prospective randomised
trial. Cases that were scored incorrectly (when compared to the
reference) or equivocal by at least nine observers were regarded as
difficult cases and are described in the results.
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The observers were asked which criteria they used for their
interpretation of the FDG-PET scan.
Statistical Analysis
Data were obtained for a sensitive and a conservative PET reading
strategy: The PET results were dichotomised by assigning equivocal
scores to either the PET-positive or to the PET-negative classifica-
tions, respectively. Mean sensitivity, specificity, positive predictive
value and negative predictive value were determined for either
strategy. A Bayesian plot was used to show the probability of proven
tumour within 6months for varying prevalences of tumour. To
illustrate the probability of tumour in time after the PET scan for the
different strategies and for different observers, a Kaplan Meier
analysis was performed. Correlation between experience and diag-
nostic performance (measured with both conservative and sensitive
strategies) and percentage of equivocal scores was evaluated.
To analyse the interobserver variability, we used agreement
statistics (κ) with a classification according to Landis et al. [31]
(Table 1). Linear-weighted kappa was used to determine interob-
server variability of the 11 observers compared to the reference
standard and pairwise compared to each other, for both conservative
and sensitive strategy.
Results
Within 6 months after the FDG-PET scan, a local recurrence
was histologically proven in seven patients (23%).
For both conservative (equivocal considered negative) and
sensitive strategies (equivocal considered positive), the accuracy
was determined per observer and depicted in a box plot (Fig. 1).
The mean data of the accuracy of the 11 observers are shown
in Table 2. For the conservative reading strategy, mean
sensitivity of 87% (range 57–100%), specificity of 81% (range
65–96%), positive predictive value of 61% (range 43–80%)
and negative predictive value of 96% (range 88–100%) were
found. For the sensitive reading strategy, mean sensitivity of
97% (range 86–100%), specificity of 63% (range 39–87%),
positive predictive value of 46% (range 33–70%) and negative
predictive value of 99% (range 93–100%) were found.
In the Bayesian plot (Fig. 2), the two strategies mainly
differ in the intermediate ranges of the prior probability of
proven recurrence. Also, these differences are larger for the
false negatives (lower corner) than for the true (and thus
false) positives.
In a Kaplan Meier analysis (Fig. 3), as expected, an
observer with a high accuracy (versus the reference) predicted
the prognosis for local disease-free control more accurately
than an observer with a low accuracy. With the conservative
strategy, for both observers, a curve was established with
significantly more local recurrences in the PET-positive than
in the PET-negative group. Seven recurrences (71%) man-
ifested within 6months after PET, no recurrences were
diagnosed between 6 and 12 months and the remaining two
recurrences were seen between 12 and 24 months.
The estimated total number of FDG-PET scans for
suspected recurrent laryngeal cancer of the observers had
assessed previously varied between 0 and 300 (experience
with dual head gamma cameras included). There was no
statistically significant association between this experience
and the number of ‘equivocal’ scores (p = 0.610, Table 3).
The equivocal category was reported at a mean of five (out
of 30 cases) per observer (17%, range 1–10). Furthermore,
we found no significant correlation between the experience
and diagnostic performance (conservative p = 0.360,
sensitive p = 0.528, Table 3).
The interobserver variability in comparison to the
reference (local recurrence within 6months after the PET
Table 1. Classification of the interobserver variability with kappa
Kappa (κ) Agreement
G0 No agreement other than agreement based on coincidence
0.01–0.19 Slight agreement
0.20–0.39 Fair agreement
0.40–0.59 Moderate agreement
0.60–0.79 Substantial agreement
0.80–0.99 Almost perfect agreement
1 Perfect agreement
Fig. 1. Accuracy for conservative and sensitive reading
strategies depicted in a box-and-whisker plot. The boxes
contain the central half of the measurements (heavy line
indicating the median). The dots are the values that are
extremely far from the central box (outliers).
Table 2. Mean pooled accuracy for conservative (equivocal = negative)
and sensitive (equivocal = positive) strategies
Conservative
strategy (%)
Sensitive
strategy (%)
Sensitivity 87 97
Specificity 81 63
Positive predictive value 61 46
Negative predictive value 96 99
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scan) showed a moderate relation [κ = 0.55; 95% confidence
interval (CI): 0.33–0.76]. The interobserver variability as
pairwise comparison of the observers, which expresses the
consistency between observers, also showed a moderate
relation (κ = 0.54; 95% CI: 0.42–0.67).
When reducing the data from a three- to a two-point
scale, the conservative strategy proved to result in a
better interobserver agreement in comparison to the
reference (κ = 0.59; 95% CI: 0.38–0.79) than the sensitive
one (κ = 0.43; 95% CI: 0.22–0.63). The same was true for
the pairwise comparison of the observers (conservative: κ =
0.58; 95% CI: 0.44–0.71, versus κ = 0.51; 95% CI: 0.37–
0.65 for SR).
There were two difficult cases, with much discrepancy
between the report of the observers and the reference (Fig. 4;
patients #5 and #9). Both cases were negative according to
the reference. Patient #5 underwent FDG-PET 5months after
the last radiotherapy fraction for a left-sided T3N1 supra-
glottic laryngeal carcinoma. Clinical suspicion of recurrence
was based on unexplained otalgia. A MRI of the neck
showed diffuse paraglottic swelling on both sides (mainly on
the right side), which could either be post-irradiation effects
or recurrent tumour according to the radiologist (Fig. 5).
Five observers scored the PET scan (Fig. 5) as equivocal and
six as positive. At direct laryngoscopy, irregular tissue at the
left aryepiglottic fold and the epiglottis was seen, but biopsy
revealed no malignancy. Three years and 2months after PET,
the patient died with lung metastases, but a local recurrence
was never detected.
Patient #9 had a PET scan 2years after completion of
radiotherapy for a left-sided T2N0 glottic carcinoma. The
PET scan (Fig. 6) was indicated because the left side of the
Fig. 2. Bayesian plot with the prior and posterior probability of proven recurrence within 6months after FDG-PET for the
conservative and the sensitive strategies.
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glottis appeared suspicious at indirect laryngoscopy. CT scan
of the neck showed a suspect area just ventral to the lesion
described on the PET scan. Seven observers scored the PET
scan as positive, three as equivocal and one as negative.
Clinical follow-up was uneventful until 2years, later direct
laryngoscopy revealed squamous cell carcinoma at the
original tumour site. The laryngectomy specimen contained
a squamous cell carcinoma of 1.5cm in diameter located in
the glottis with tumour extension into the thyroid cartilage.
The criteria the observers used for their interpretation
were information derived from the PET scan, such as
localisation, (a)symmetry and aspect of suspicious areas,
diffuse versus focal lesions and the intensity of the
suspicious areas compared to the intensity of the back-
ground, in combination with the clinical data (localisation of
primary tumour, interval between radiation and PET).
Discussion
In the present study, we analysed the performance of 11
observers from the eight head and neck cancers centres in
The Netherlands for the assessment of FDG-PET scans from
Fig. 3. Kaplan Meier analysis of a proven recurrence after PET, with stratification of the negative and positive assessed
patients using the sensitive (a, b) and conservative (c, d) strategies by an observer with high accuracy (observer 1; a, c) and an
observer with low accuracy (observer 2; b, d).
298 L. van der Putten, et al.: FDG-PET for Recurrent Laryngeal Carcinoma
patients who were suspected of having a local recurrence of
laryngeal carcinoma after primary radiotherapy.
We found a reasonable chance-corrected proportional
observer agreement, both in comparison to the reference
standard and pairwise. It is difficult to predict how the
agreement would change if a larger sample size was studied.
To the best of our knowledge, this is the first study that
examines the interobserver variability of more than two
observers from different institutes in the detection of
recurrent laryngeal carcinoma with FDG-PET. Many authors
stress the importance of interobserver agreement [32, 33].
Fakhry et al. [34] studied the interobserver variability
between two observers of FDG-PET in the detection of
recurrent head and neck squamous cell carcinoma and found
a good agreement (intraclass correlation coefficient 990). A
substantial agreement was also described for metastatic
disease. Bohdiewicz et al. [35] found a 90% agreement
between two observers who reviewed FDG-PET scans for
metastatic disease in the spinal cord, and Lim et al. [36]
found a kappa of 0.68 for three observers who reviewed
FDG-PET scans for peritoneal metastases. Hashimoto et al.
[37] evaluated lung nodules with two observers of FDG-PET
and found a kappa of 0.65. In a study performed by Zijlstra
et al. [38], 11 observers reviewed FDG-PET scans for
suspicion of recurrent lymphoma in 82% to 94% of the
tumour-positive patients and 45% of the tumour-negative
patients, which were in accordance with the experts.
Because the observer panel in this study consisted of
nuclear physicians from all Dutch Head and Neck Cancer
Centres, the results give a good impression of the overall
diagnostic performance of PET for suspected laryngeal
Table 3. Correlations with log-experience between experience of the
observers and the number of equivocal score, the accuracy with equivocal
as negative (conservative) or positive (sensitive)
r p 95% CI of r
Number of equivocals 0.175 0.610 -0.464–0.694
Accuracy (conservative) 0.307 0.360 -0.347–0.760
Accuracy (sensitive) 0.215 0.528 -0.499–0.669
r Correlation coefficient, p significance, 95% CI 95% confidence interval
Fig. 4. All 30 cases and the results of the review (correct, equivocal, incorrect) compared to the reference standard (numbers
of observers).
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recurrence after radiotherapy in The Netherlands. Especially,
since the interobserver agreement was reasonable, an
acceptable reproducibility and thereby a general applicability
of these results is assumed.
As expected, sensitivity and specificity varied inversely
with the threshold of test positivity. Our data (mean sensitivity
ranging from 87% to 97%, specificity from 63% to 81%)
appear to reflect the distribution of such measures reported in
Fig. 5. Patient 5: MRI (STIR, axial) with diffuse paraglottic swelling on both sides, mainly right (arrows). PET (axial) with
abnormal supraglottic ventral uptake, on the right side more than on the left side (arrows). Below the arrows is a region with
abnormal uptake, probably caused by uptake in the crico-arythenoid muscle.
Fig. 6. FDG-PET scan of case 9 (axial, coronal and sagittal images) reviewed as tumour positive by seven observers,
equivocal by three observers and negative by one observer (arrows indicate region suspected of tumour).
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the literature, with sensitivities ranging from 80% to 100%
and specificities from 63% to 100% [12, 26–28, 39, 40].
Remarkably, no significant correlation between the
accuracy and the experience of the observer was found.
Also, no correlation was found between experience of the
observers and the number of non-conclusive reports. At first
glance, these findings may suggest that no specific experi-
ence is needed with FDG-PET for laryngeal carcinoma.
Another explanation for this finding could be the lack of
clinical feedback during daily practice in which a learning
curve cannot be established. Therefore, regular feedback
during daily practice seems essential also in situations where
proof of presence or absence of disease may be obtained
several months after PET. Finally, we recognise that the
sample size was relatively small and that some observers
reported that they were unfamiliar with interpretation of
images without attenuation correction. However, the perfor-
mance of these observers was not clearly different from the
others. Moreover, considering the 95% confidence intervals
of the correlation coefficients, it seems unlikely that a larger
sample size would change these findings. Unfortunately, it
was not possible to compare the correlations between
accuracy and the experience of the observer or the number
of equivocal scores with previous studies, as previous
studies used two or three experienced nuclear physicians
without differentiation of the level of experience or the
relation with equivocal scores. Zijlstra et al. [38] reported
that the experts did not have any equivocal scores, while the
less experienced observers did have equivocal scores.
A variable amount of cases were scored equivocal (a
median of 17% equivocal reports per observer). Although
the number of non-conclusive scores differed greatly per
observer (range 0–10), this indicates that in contrast to how
data are typically reported, dichotomous results of FDG-PET
for recurrent carcinoma may be regarded as an artificial and
unwanted simplification. To explore the effect on diagnostic
performance of this phenomenon, we dichotomised the data.
The conservative strategy in which the equivocal scores
were analysed as negative resulted in a better overall
accuracy and a better interobserver agreement (kappa 0.59
and 0.58) than the sensitive strategy (kappa 0.43 and 0.51).
In our population, the prevalence of histologically proven
recurrence was 23%. Because the mean reported prevalence
is 50% [14, 25, 27], we compared these prevalences in a
Bayesian plot. When the prevalence is 50%, the difference
between the two strategies for a negative PET scan, in favour
of the sensitive strategy, is larger as compared to the
prevalence in the present study.
We assume that in clinical practice, the sensitive reading
is used if FDG-PET is used to select patients suspected of
recurrent laryngeal carcinoma after radiotherapy for direct
laryngoscopy under general anaesthesia. For the physician,
the risk of missing a recurrence probably outweighs a futile
direct laryngoscopy because early detection of a recurrence
can be important for salvage surgery and clinical outcome.
An inherent disadvantage of sensitive reading is the higher
percentage of false positives and subsequently futile direct
laryngoscopies under general anaesthesia and more interob-
server variability. It can be expected that the interobserver
agreement has improved by the feedback received after the
assessment.
We used a disease-free follow-up of 6months as reference
standard of patients without recurrence because we assume
that local disease manifest itself within this period. Extend-
ing this period carries the risk to include recurrent disease
that developed after the PET scan. If local recurrences were
not detected within the first 6months, these were diagnosed
at least 21months after the PET scan. It seems highly
unlikely that the lead-time of PET would be that long, but
we admit that we cannot exclude the possibility of a very
slow growing recurrence.
As was shown in the Kaplan Meier analyses (Fig. 3), a
negative PET scan was highly predictive for local control,
especially in the first 12months. This suggests that patients
with a negative PET scan might be spared a futile
laryngoscopy under general anaesthesia and that regular
follow-up might be sufficient.
While false-positive reading tends to be a problem, the
negative predictive value of FDG-PET is high in both
the conservative (96%) and the sensitive strategy (99%). The
negative predictive value is, of course, dependent on the
prevalence of disease. In the present study, the prevalence
was only 23%. In the PET literature, the mean prevalence
appears to be about 50% (manuscript in preparation), and
high negative predictive values for different prevalence are
reported [41]. Therefore, it can be anticipated that a negative
FDG-PET excludes recurrent disease with a high certainty.
With this unique characteristic, FDG-PET may be safely
used as the first diagnostic step of triage for invasive
procedures in patients suspected of recurrent laryngeal
tumour. By filtering the patients with a negative PET scan
out of the further diagnostic process, the percentage of futile
diagnostic laryngoscopies can probably be diminished.
To further investigate the potential of FDG-PET for this
indication, a prospective study with more patients is
recommended. In the current study, the images were not
attenuation-corrected. In the future, the fused PET-CT will
probably take over the PET alone. Besides the anatomical
information of the CT, it also offers the possibility to easily
determine the ‘standard uptake values’ for objective assess-
ment. For the present indication, selection of patients with
suspicion of recurrent laryngeal carcinoma after radiotherapy
for direct laryngoscopy under general anaesthesia, detailed
anatomical information is probably not essential. Uptake in
the laryngeal area, which indicates further examination, can
be assessed on PET alone. For this indication, no literature is
available about the diagnostic value of PET-CT in compar-
ison with PET alone. PET-CT may yield slightly different
results, and this will be subject of further study [29]. Another
relative disadvantage of the present study is the varying
interval between the last radiation and the PET scan, with a
minimum interval of 2.4 months. McGuirt et al. [41] and
L. van der Putten, et al.: FDG-PET for Recurrent Laryngeal Carcinoma 301
Ryan et al. [28] concluded that the accuracy of PET is
significantly higher for an interval more than 3 months
compared to 1 month.
Conclusions
While acknowledging that additional confirmation is necessary,
we propose in view of the acceptable interobserver agreement
that FDG-PET yields good negative predictive value for the
detection of recurrent laryngeal carcinoma after radiotherapy. It
could therefore be used as a first diagnostic step and may reduce
the percentage of futile invasive diagnostics.
Acknowledgements. Due to the participation of the following nuclear
physicians, it was possible to conduct a unique study on interobserver
variability. We wish to thank the following observers: A.I.J. Arens, MD
(AZM), J.W. van Isselt, MD, PhD (UMCU), B.L.R. Kam, MD (Erasmus
MC), W. Oyen, MD, PhD (UMCN St. Radboud), J. Pruim, MD, PhD
(UMCG), M.P.M. Stokkel, MD, PhD (LUMC), G.J.J. Teule, MD, PhD
(AZM), R.A. Valdes Olmos, MD, PhD (NKI/AvL) and R. Valkema, MD,
PhD (Erasmus MC).
Open Access. This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any non-
commercial use, distribution, and reproduction in any medium, provided
the original author(s) and source are credited.
References
1. Siesling S, van Dijck JA, Visser O, Coebergh JW (2003) Trends in
incidence of and mortality from cancer in The Netherlands in the period
1989–1998. Eur J Cancer 39:2521–2530
2. Bourhis J, Overgaard J, Audry H et al (2006) Hyperfractionated or
accelerated radiotherapy in head and neck cancer: a meta-analysis.
Lancet 368:843–854
3. Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy
added to locoregional treatment for head and neck squamous-cell
carcinoma: three meta-analyses of updated individual data. MACH-NC
Collaborative Group. Meta-Analysis of Chemotherapy on Head and
Neck Cancer. Lancet 355:949–955
4. Moyer JS, Wolf GT, Bradford CR (2004) Current thoughts on the role
of chemotherapy and radiation in advanced head and neck cancer. Curr
Opin Otolaryngol Head Neck Surg 12:82–87
5. Hillman RE, Walsh MJ, Fisher SG, Wolf GT, Hong WK (1998)
Functional outcomes following treatment for advanced laryngeal
cancer. Part I—voice preservation in advanced laryngeal cancer. Part
II—laryngectomy rehabilitation: the state of the art in the VA system.
Ann Otol Rhinol Laryngol 107:2–27
6. Terrell JE, Fisher SG, Wolf GT (1998) Long-term quality of life after
treatment of laryngeal cancer. Arch Otolaryngol Head Neck Surg
124:964–971
7. Di Martino E, Nowak B, Hassan HA et al (2000) Diagnosis and staging
of head and neck cancer—a comparison of modern imaging modalities
(positron emission tomography, computed tomography, color-coded
duplex sonography) with panendoscopic and histopathologic findings.
Arch Otolaryngol Head Neck Surg 126:1457–1461
8. Gussack GS, Hudgins PA (1991) Imaging modalities in recurrent head
and neck tumors. Laryngoscope 101:119–124
9. Harnsberger HR, Mancuso AA, Muraki AS, Parkin JL (1983) The
upper aerodigestive tract and neck—CT evaluation of recurrent tumors.
Radiology 149:503–509
10. McGuirt WF, Greven K, Williams D et al (1998) PET scanning in head
and neck oncology: a review. Head Neck 20:208–215
11. Nowak B, Di Martino E, Janicke S et al (1999) Diagnostic evaluation of
malignant head and neck cancer by F-18-FDG PET compared to CT/
MRI. Nuklearmediziner 38:312–318
12. Bongers V, Terhaard CJ, van Isselt JW, Hordijk GJ, van Rijk PP (2000)
Dual-head FDG-PET for the detection of recurrent laryngeal cancer
compared with histopathological biopsy results and minimally 1year
clinical follow-up. J Nucl Med 41:287P
13. Wong RJ, Lin DT, Schoder H et al (2002) Diagnostic and prognostic
value of [(18)F]fluorodeoxyglucose positron emission tomography for
recurrent head and neck squamous cell carcinoma. J Clin Oncol
20:4199–4208
14. Greven KM, Williams DW, Keyes JW, McGuirt WF, Watson NE, Case
LD (1997) Can positron emission tomography distinguish tumor
recurrence from irradiation sequelae in patients treated for larynx
cancer? Cancer J Sci Am 3:353–357
15. Brouwer J, Bodar EJ, de Bree R et al (2004) Detecting recurrent
laryngeal carcinoma after radiotherapy: room for improvement. Eur
Arch Otorhinolaryngol 261:417–422
16. Sigg MB, Steinert H, Gratz K, Hugenin P, Stoeckli S, Eyrich GK
(2003) Staging of head and neck tumors: [F-18]fluorodeoxyglucose
positron emission tomography compared with physical examination and
conventional imaging modalities. J Oral Maxillofac Surg 61:1022–1029
17. Fischbein NJ, Aassar OS, Caputo GR et al (1998) Clinical utility of
positron emission tomography with F-18-fluorodeoxyglucose in detect-
ing residual/recurrent squamous cell carcinoma of the head and neck.
ANJR Am J Neuroradiol 19:1189–1196
18. Hanasono MM, Kunda LD, Segall GM, Ku GH, Terris DJ (1999) Uses
and limitations of FDG positron emission tomography in patients with
head and neck cancer. Laryngoscope 109:880–885
19. Lowe VJ, Boyd JH, Dunphy FR et al (2000) Surveillance for recurrent
head and neck cancer using positron emission tomography. J Clin
Oncol 18:651–658
20. Muylle K, Castaigne C, Flamen P (2005) F-18-fluoro-2-deoxy-D-
glucose positron emission tomographic imaging: recent developments
in head and neck cancer. Curr Opin Oncol 17:249–253
21. Kitagawa Y, Nishizawa S, Sano K et al (2003) Prospective comparison
of F-18-FDG PET with conventional imaging modalities (MRI, CT, and
Ga-67 scintigraphy) in assessment of combined intraarterial chemo-
therapy and radiotherapy for head and neck carcinoma. J Nucl Med
44:198–206
22. Rusthoven KE, Koshy M, Paulino AC (2005) The role of PET–CT
fusion in head and neck cancer. Oncology (Williston Park) 19:241–246
23. Goerres GW, Schmid DT, Bandhauer F et al (2004) Positron emission
tomography in the early follow-up of advanced head and neck cancer.
Arch Otolaryngol Head Neck Surg 130:105–109
24. Lowe VJ, Dunphy FR, Varvares M et al (1997) Evaluation of
chemotherapy response in patients with advanced head and neck cancer
using [F-18]fluorodeoxyglucose positron emission tomography. Head
Neck 19:666–674
25. McGuirt WF, Greven KM, Williams DW, Keyes JW, Watson N (1998)
Laryngeal radionecrosis versus recurrent cancer: a clinical approach.
Ann Otol Rhinol Laryngol 107:293–296
26. Stokkel MP, Terhaard CH, Mertens IJ, Hordijk GJ, van Rijk PP (1998)
Fluorine-18-FDG detection of laryngeal cancer postradiotherapy using
dual-head coincidence imaging. J Nucl Med 39:1385–1387
27. Terhaard CH, Bongers V, van Rijk PP, Hordijk GJ (2001) F-18-fluoro-
deoxy-glucose positron-emission tomography scanning in detection of
local recurrence after radiotherapy for laryngeal/pharyngeal cancer.
Head Neck 23:933–941
28. Ryan WR, Fee WE Jr, Le QT, Pinto HA (2005) Positron-emission
tomography for surveillance of head and neck cancer. Laryngoscope
115:645–650
29. de Bree R, van der Putten L, Hoekstra OS et al (2007) A randomized
trial of PET scanning to improve diagnostic yield of direct laryngos-
copy in patients with suspicion of recurrent laryngeal carcinoma after
radiotherapy. Contemp Clin Trials 28:705–712
30. Joshi U, Raijmakers PG, Riphagen II, Teule GJ, van LA, Hoekstra OS
(2007) Attenuation-corrected vs. nonattenuation-corrected 2-deoxy-2-
[F-18]fluoro-D-glucose-positron emission tomography in oncology: a
systematic review. Mol Imaging Biol 9:99–105
31. Landis JR, Koch GG (1977) The measurement of observer agreement
for categorical data. Biometrics 33:159–174
32. Jones TD, Cheng L (2006) Papillary urothelial neoplasm of low
malignant potential: evolving terminology and concepts. J Urol
175:1995–2003
33. Christensen JA, Fletcher JG, Fidler JL et al (2004) Intraductal papillary
mucinous neoplasms of the pancreas: CT patterns of recurrence and
302 L. van der Putten, et al.: FDG-PET for Recurrent Laryngeal Carcinoma
multiobserver performance in detecting recurrent neoplasm after
surgical resection. AJR Am J Roentgenol 183:1367–1374
34. Fakhry N, Lussato D, Jacob T, Giorgi R, Giovanni A, Zanaret M (2007)
Comparison between PET and PET/CT in recurrent head and neck
cancer and clinical implications. Eur Arch Otorhinolaryngol 264:531–
538
35. Bohdiewicz PJ, Wong CY, Kondas D, Gaskill M, Dworkin HJ (2003)
High predictive value of F-18 FDG PET patterns of the spine for
metastases or benign lesions with good agreement between readers.
Clin Nucl Med 28:966–970
36. Lim JS, Kim MJ, Yun MJ et al (2006) Comparison of CT and 18F-FDG
pet for detecting peritoneal metastasis on the preoperative evaluation for
gastric carcinoma. Korean J Radiol 7:249–256
37. Hashimoto Y, Tsujikawa T, Kondo C et al (2006) Accuracy of
PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake
below the standardized uptake value of 2.5. J Nucl Med 47:426–
431
38. Zijlstra JM, Comans EF, van Lingen A et al (2007) FDG PET in
lymphoma: the need for standardization of interpretation. An observer
variation study. Nucl Med Commun 28:798–803
39. Alvarez Perez RM, Borrego DI, Vazquez AR, Ruiz Franco-Baux J,
Ceballo Pedraja JM, Esteban OF (2006) Evaluation of efficacy and
clinical impact of positron emission tomography with 18F fluoro-
deoxyglucose (FDG) in patients with suspicion of recurrent laryngeal
carcinoma. Acta Otorrinolaringol Esp 57:134–139
40. Schoder H, Yeung HWD (2004) Positron emission imaging of head and
neck cancer, including thyroid carcinoma. Sem Nucl Med 34:180–197
41. McGuirt WF, Greven KM, Keyes JW et al (1995) Positron emission
tomography in the evaluation of laryngeal carcinoma. Ann Otol Rhinol
Laryngol 104:274–278
L. van der Putten, et al.: FDG-PET for Recurrent Laryngeal Carcinoma 303
